Similarly, CTGF—a YAP/TAZ–TEAD target that drives fibrosis and angiogenesis—is neutralized by the monoclonal antibody pamrevlumab (FG-3019), currently being tested in oncology to modulate tumor stroma90. The gene discussed is YAP1; the disease is neoplasm.